12:00 AM
 | 
Nov 25, 2013
 |  BC Week In Review  |  Clinical News  |  Clinical Results

MiStent: Phase II data

The open-label, international Phase II DESSOLVE I trial in 30 patients with stable or unstable angina pectoris showed that the MiStent sirolimus-eluting coronary stent led to minimal progression...

Read the full 118 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >